Mira Pharmaceuticals (MIRA) Non Operating Income (2024 - 2025)
Mira Pharmaceuticals (MIRA) posted Non Operating Income of -$158494.0 for Q4 2025, down 188.39% sequentially from $179312.0 in Q3 2025, and down 515.94% YoY from $38105.0 in Q4 2024.
Mira Pharmaceuticals (MIRA) Non Operating Income (2024 - 2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 2 years of Non Operating Income data on file, last reported at -$158494.0 in Q4 2025.
- Quarterly Non Operating Income fell 515.94% year-over-year to -$158494.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $58816.0 (changed N/A YoY) and the FY2025 annual result came in at $50627.0, down 69.44% from the prior year.
- Non Operating Income eased to -$158494.0 in Q4 2025 per MIRA's latest filing, from $179312.0 in the prior quarter.
- The five-year high for Non Operating Income was $179312.0 in Q3 2025, with the low at -$158494.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -65.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -294.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -2.31 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | -158,494.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -158,494.00 |
| Sep 30, 2025 | 179,312.00 |
| Jun 30, 2025 | -107.00 |
| Dec 31, 2024 | 38,105.00 |
| Sep 30, 2024 | 37,752.00 |